Virginia could potentially have low-nicotine cigarettes available by the end of the year. These cigarettes, created by 22nd Century Group, contain 95% less nicotine than regular cigarettes. This development comes as Virginia performed poorly in all categories of the American Lung Association's 2023 State of Tobacco Control Report.
According to John Miller, the Tobacco Division president for 22nd Century Group, these low-nicotine cigarettes are another option for nicotine replacement therapy. Despite the availability of nicotine gums and lozenges, there are still 35 million smokers in the United States. The Food and Drug Administration (FDA) recognizes that there is no one-size-fits-all solution for smoking cessation.
California, Florida, and Texas will be the first states to offer the low-nicotine cigarettes this month. The plan is to expand to 18 other states later in the year. While some groups have concerns about FDA regulation, research has shown that reducing nicotine levels in cigarettes can reduce addiction and toxicant exposure.
During market testing, safety has been a priority, and it has become evident that youth smokers are not interested in these cigarettes. Miller acknowledges that youth smoking issues have shifted towards vapor products. The focus now is on ensuring safety and targeting the right consumer demographic.
Reference:
[1] Virginia Could See Low-Nicotine Cigarettes By End of 2023
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
